These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35585427)

  • 1. Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial.
    Cavanagh B; Gomes PJ; Starr CE; Nichols KK; Brady TC
    Ophthalmol Ther; 2022 Aug; 11(4):1449-1461. PubMed ID: 35585427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis.
    Starr CE; Nichols KK; Lang JR; Brady TC
    Clin Ophthalmol; 2023; 17():3867-3875. PubMed ID: 38105911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure.
    Clark D; Karpecki P; Salapatek AM; Sheppard JD; Brady TC
    Clin Ophthalmol; 2022; 16():15-23. PubMed ID: 35018093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial.
    Clark D; Cavanagh B; Shields AL; Karpecki P; Sheppard J; Brady TC
    Am J Ophthalmol; 2021 Oct; 230():60-67. PubMed ID: 33945820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model.
    Torkildsen G; Narvekar A; Bergmann M
    Clin Ophthalmol; 2015; 9():1703-13. PubMed ID: 26392751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
    Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
    Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
    Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
    Friedlaender MH; Harris J; LaVallee N; Russell H; Shilstone J
    Ophthalmology; 2000 Dec; 107(12):2152-7. PubMed ID: 11097587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis.
    Gomes PJ; Ciolino JB; Arranz P; Hernández G; Fernández N
    J Investig Allergol Clin Immunol; 2024 Jun; 34(3):167-176. PubMed ID: 36811846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
    Abelson MB; Turner D
    Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis.
    Torkildsen GL; Abelson MB; Gomes PJ
    Clin Ther; 2008 Jul; 30(7):1272-82. PubMed ID: 18691986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
    Abelson MB; Gomes P; Crampton HJ; Schiffman RM; Bradford RR; Whitcup SM
    Clin Ther; 2004 Jan; 26(1):35-47. PubMed ID: 14996516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vehicle-Controlled, Phase 2 Clinical Trial of a Sustained-Release Dexamethasone Intracanalicular Insert in a Chronic Allergen Challenge Model.
    Torkildsen G; Abelson MB; Gomes PJ; McLaurin E; Potts SL; Mah FS
    J Ocul Pharmacol Ther; 2017 Mar; 33(2):79-90. PubMed ID: 28072552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study.
    Abelson MB; Gomes PJ; Vogelson CT; Pasquine TA; Gross RD; Turner FD; Wells DT; Bergamini MV; Robertson SM
    Clin Ther; 2004 Aug; 26(8):1237-48. PubMed ID: 15476905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM; Tekelioglu Y; Turk A; Akyol N
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease.
    Clark D; Tauber J; Sheppard J; Brady TC
    Am J Ophthalmol; 2021 Jun; 226():22-31. PubMed ID: 33529588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Punctal Occlusion on Ocular Itching and Conjunctival Redness Associated with Allergic Conjunctivitis.
    Silverstein SM; Sato MA; Meier EJ; Dai S; Bauskar A; Depperschmidt K; Blender N; Vantipalli S; Goldstein MH; Gurses Ozden R
    Curr Eye Res; 2023 Sep; 48(9):781-787. PubMed ID: 37199292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis.
    Verin P; Easty DL; Secchi A; Ciprandi G; Partouche P; Nemeth-Wasmer G; Brancato R; Harrisberg CJ; Estivin-Ebrardt C; Coster DJ; Apel AJ; Coroneo MT; Knorr M; Carmichael TR; Kent-Smith BT; Abrantes P; Leonardi A; Cerqueti PM; Modorati G; Martinez M
    Am J Ophthalmol; 2001 Jun; 131(6):691-8. PubMed ID: 11384563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.